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Little is known about the impact of pretreatment drug resistance (PDR) on the efficacy of
second generation integrase inhibitors. We sequenced pretreatment plasma specimens from
the ADVANCE trial (NCT03122262). Our primary outcome was 96-week virologic success,
defined as a sustained viral load <1000 copies/mL from 12 weeks onwards, <200 copies/mL
from 24 weeks onwards, and <50 copies/mL after 48 weeks. Here we report how this
outcome was impacted by PDR, defined by the World Health Organization (WHO) mutation
list. Of 1053 trial participants, 874 (83%) have successful sequencing, including 289 (33%)
randomized to EFV-based therapy and 585 (67%) randomized to DTG-based therapy.
Fourteen percent (122/874) have ≥1 WHO-defined mutation, of which 98% (120/122) are
NNRTI mutations. Rates of virologic suppression are lower in the total cohort among those
with PDR 65% (73/112) compared to those without PDR (85% [605/713], P < 0.001), and
for those on EFV-based treatment (60% [12/20] vs 86% [214/248], P = 0.002) and for
those on DTG-based treatment (61/92 [66%] vs 84% [391/465] P < 0.001, P for interaction
by regimen 0.49). Results are similar in multivariable models adjusted for clinical char-
acteristics and adherence. NNRTI resistance prior to treatment is associated with long-term
failure of integrase inhibitor-containing first-line regimens, and portends high rates of first-
line failure in sub Saharan Africa.
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The increasing prevalence of non-nucleoside reverse tran-scriptase inhibitor (NNRTI) resistance in those initiatingor re-initiating antiretroviral therapy (ART)1, along with
the advantageous safety, potency, and cost-effectiveness char-
acteristics of dolutegravir (DTG)2, prompted the World Health
Organization (WHO) to recommend DTG-based ART as a pre-
ferred first-line regimen3. However, recent concerns about DTG
have emerged. For example, early data suggested a slight
increased risk of neural tube defects following DTG exposure in
pregnancy, although more recent data have been reassuring4.
Secondly, greater weight gain was observed in patients treated
with DTG compared to efavirenz (EFV) in two clinical trials in
sub-Saharan Africa, as well as in cohort studies from the North
America and Europe, leading to concerns about long-term effects
of obesity with lifelong ART5–9.
Whilst cost-effectiveness analyses continue to support the use
of DTG as first-line therapy despite these issues10, the WHO and
others are revisiting targeted use of efavirenz (EFV). Concerns
remain about the use of EFV with widespread NNRTI resistance,
which exceeds 10−15% in much of sub-Saharan Africa11. Pre-
treatment NNRTI resistance has been associated with a 2−3-fold
greater risk of virologic failure (VF) for people initiating NNRTI-
based regimens, both with older combinations such as nevirapine
(NVP) and with EFV12–14. By contrast, the ANRS 12249 Treat-
ment as Prevention Trial15 reported that the most common
NNRTI mutation, K103N, when detected alone, was not asso-
ciated with increased risk of VF on an NNRTI-based single tablet
regimen containing tenofovir, emtricitabine and efavirenz16. A
study in Kenya similarly suggested isolated K103N might have
limited impact on EFV-based ART17.
These conflicting data have generated controversy in the field
on optimal first-line regimens to balance safety, tolerability, cost,
and the impact of circulating NNRTI drug resistance on virologic
outcomes. Although clinical trial data in the United States suggest
that DTG performs exceptionally well in ART-naive individuals
and as a switch regimen in the absence of significant background
resistance18–20, there is relatively little data available on the effi-
cacy of DTG in the context of high circulating NNRTI resistance.
In the DAWNING trial, in which individuals failing NNRTIs
were randomized to DTG or lopinavir/ritonavir, and over 90%
had some evidence of NNRTI resistance, approximately 84% of
individuals in the DTG arm achieved virologic suppression at
48 weeks. Notably the proportion of people suppressed at
48 weeks on DTG arm was lower than in most prior clinical trials,
albeit of first-line therapy21. As such, additional studies are nee-
ded to better elucidate the impact of pretreatment NNRTI drug
resistance on virologic outcomes with both EFV-based and DTG-
based used first-line regimens in the region.
Here we report results of next-generation sequencing of stored
plasma specimens from participants in the ADVANCE clinical
trial to determine the contributions of NNRTI pretreatment drug
resistance (PDR) on 96-week virologic outcomes for individuals
initiating EFV- and DTG-based ART. We hypothesize that
NNRTI PDR significantly affects efficacy of EFV-containing
regimens but has a negligible effect on outcomes for those initi-
ating DTG-based therapy.
Results
Study population. A total of 1053 individuals were enrolled in
the ADVANCE trial. Of these, 991 (94%) consented for specimen
storage and had pretreatment plasma available for testing, and
874 (83%) had successful sequencing of a pretreatment plasma
specimen (Fig. 1). We found no differences in clinical or demo-
graphic characteristics between those who successfully underwent
sequencing and those who did not (Supplementary information).
Of participants included in PDR analyses, 289 (33%) were ran-
domized to an EFV-based regimen and 585 (67%) were rando-
mized to a DTG-based regimen. At the time of data extraction, all
had completed observation up to 96 weeks. A total of 48 and 82
individuals were excluded from our primary and secondary
analyses, respectively, for not remaining in the study to 12 or
24 weeks. There were no differences by treatment regimen in
clinical or demographic factors in our primary analytic sample
(Table 1). However, individuals starting DTG-based regimens
had a higher prevalence of PDR than those initiating EFV-based
regimens (16.5 vs 7.4%, P < 0.001).
Pretreatment drug resistance. Approximately 14% (122/874) of
individuals had at least one WHO-defined PDR mutation at
variant frequencies of 20% or greater (Fig. 2). The majority of
PDR was accounted for by mutations conferring resistance to
NNRTIs, with over 98% (120/122) of those harboring WHO-
defined PDR having at least one NNRTI mutation. The most
common single mutation was K103N, present in 9% (81/874).
Only 20 (2%) individuals had a nucleoside reverse transcriptase
inhibitor (NRTI) mutation, with M184V being the most com-
mon, present in 12 (1%) individuals, followed by K65R, which
was present in 8 (1%) individuals. The combination of at least one
NRTI mutation and one NNRTI mutation was identified in 18
(2%) participants.
Virologic suppression rates. After excluding 48 individuals who
were censored before 12 weeks, virologic success over 96 weeks of
observation, as defined by our primary outcome, was achieved in
approximately 83% of study participants (678/825, Table 2). In
the overall cohort, rates of virologic suppression were significantly
lower in those with PDR 65% (73/112) compared to those
without PDR (85% [605/713], P < 0.001). This pattern was true
for participants initiating EFV-based ART (60% [12/20] vs 86%
[214/248], P= 0.002) and DTG-based ART (61/92 [66%] vs 84%
[391/465], P value < 0.001, Fig. 3).
In multivariable regression models, PDR remained a strong
predictor of virologic success (AOR 0.38, 95%CI 0.21, 0.61) after
adjustment for demographic and clinical factors, and both self-
reported and pill count-based adherence, as well as additive
effects of PDR and adherence in both the EFV and DTG arms
(Table 3 and Fig. 4). The effect size and confidence interval
estimated would mean that an unmeasured confounder would
require an odds ratio of 2.7 or greater with both PDR and
virologic suppression (conditional on other confounders, includ-
ing self-reported adherence) to reduce the effect seen between
PDR and virologic success to the null22. Viral suppression was
also lower in those with higher baseline viral loads and in those
with lower self-reported adherence. The effect of PDR did not
differ by treatment arm (P value for interaction term by
regimen= 0.42). Rates of virologic success were higher for both
regimens for those with and without PDR in our secondary
outcome, which assessed for persistent virologic failure with two
consecutive viral loads >200 copies/mL, although the effect of
PDR persisted (85% [73/86] vs 94% 428/453], P= 0.001 for
DTG-based ART; 68% [13/19] vs 93% [217/233], P < 0.001 for
EFV-based ART, Table 2). The effect of PDR on treatment
outcomes persisted as well as for both the FDA 48-week and 96-
week Snapshot analyses, including in multivariable analyses
(Supplementary information). Among those with the TDF-
associated resistance mutation K65R at baseline (n= 8), two
were in the EFV arm (both failures) and of the six in the DTG
arm, 2/6 (33%) achieved 96-week virologic suppression as defined
by the primary outcome measure. Participants with K65R all had
NNRTI mutations and 6/8 (75%) had M184V.
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In contrast to the effect seen with long-term virologic
outcomes, PDR only had an effect on initial virologic response
for individuals on EFV-based ART, but not those on DTG-based
ART. The change in log10 viral load from enrollment to week 12
was greater for those without PDR in the EFV arm (1.89 vs 2.61
log10 copies/mL, P < 0.001), but not in the DTG arms (2.76 vs
2.68 log10 copies/mL, P < 0.43, P= 0.001 for interaction between
arms, Table 2, Supplementary information). In survival analyses,
individuals in the EFV arm with PDR experienced a longer time
to suppression than whose without PDR (P= 0.04 by log-rank
testing), whereas those with and without PDR had similar time to
initial suppression in the DTG arms (P= 0.54 by log-rank testing,
Supplementary information). In adjusted Cox proportional
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Fig. 1 Study schema. Study schema showing numbers of participants with plasma samples, successful sequencing and numbers in primary and secondary
outcomes.
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those on EFV-based ART (AHR 0.58, 95%CI 0.35, 0.96), but not
for those DTG-based ART (AHR 1.01, 95%CI 0.80, 1.27).
We considered the impact of isolated K103N (as majority virus
population, >20%) on virologic response to EFV and DTG
(Supplementary information). Rates of virologic suppression were
similar in participants taking EFV-based ART with and without
the K103N mutation, although the number of individuals with
K103N was small in this arm (n= 8). Isolated K103N was
associated with lower virologic success for individuals on DTG-
based ART, with the exception of our secondary outcome, for
which the effect size was similar but the effect was not statistically
significant.
We next examined the impact of minority variant PDR in
2−20% of viral quasispecies on outcome of first-line ART.
Individuals with mutations in minority populations had similar
virologic outcomes as those without PDR overall, and for both
those taking DTG- or EFV-based ART (Supplementary
information). We found similar effects of PDR on virologic
success in analyses stratified by EFV vs DTG-based treatment
(Supplementary information). In a subset of 38 individuals who
had sequencing data available both prior to enrollment and at the
time of failure, we found that new NRTI and NNRTI mutations
developed among those in the EFV-based ART arm in 31% (5/16)
and 40% (4/10) of individuals respectively, but that new
resistance in the reverse transcriptase gene was rare among those
in the DTG-based ART arms (6% [1/17] new NRTI mutations
and 0% (0/11) new NNRTI mutations, Supplementary informa-
tion). Finally, we found no difference in the effect of PDR on any
outcomes in sub-analyses restricted to sequences with at least
1000× average depth coverage (Supplementary information).
Discussion
We report a strong association between drug resistance before
treatment initiation, primarily to the NNRTI class, and virologic
failure for people initiating first-line ART in the ADVANCE
clinical trial. The effect was seen among individuals in the EFV
arm and DTG arms, and persisted after adjusting for self-reported
and pill count-based adherence and baseline viral load. When we
considered a secondary outcome, which focused on persistent
virologic failure (two or more consecutive visits with a high viral
load), the effect of PDR on DTG persisted, but to a lower degree.
In contrast to the effects seen for long-term outcomes, we did not
find that PDR had an impact on time to initial suppression or
change in quantified viral load from enrollment to 12 weeks,
suggesting that NNRTI PDR affects longer-term maintenance of
suppression for DTG-based ART or via a non-virally mediated
behavioral mechanism. Nonetheless, the finding that NNRTI
resistance appears to ultimately predict treatment failure among
individuals initiating DTG-based ART in LMIC was unexpected,
and to our knowledge not previously reported in the literature.
A virologic mechanism to explain our findings has not been
established. NNRTI mutations are not known to affect suscept-
ibility of DTG. The observed effect we identified may be
Table 1 Cohort characteristics for participants who completed pretreatment HIV drug resistance testing and included in our






Female sex (n, %) 153 (56.9%) 341 (61.2%) 0.23
Age (median, IQR) 32 (27−37) 32 (27−38) 0.83
Married or partner (n, %) 60 (22.3%) 108 (19.4%) 0.34
Tertiary education (n, %) 18 (6.7%) 51 (9.2%) 0.22
Employed (n, %) 170 (63.7%) 349 (63.8%) 0.97
Pretreatment CD4 count (n, %) 0.58
≤200 cells/μL 80 (29.7%) 179 (32.1%)
201−350 cells/μL 81 (30.1%) 166 (29.8%)
351−500 cells/μL 58 (21.6%) 99 (17.8%)
>500 cells/μL 50 (18.6%) 118 (20.3%)
Pretreatment viral load (n, %) 0.33
<10,000 copies/mL 89 (33.1%) 171 (30.7%)
10,000−100,000 copies/mL 113 (42.0%) 264 (47.4%)
>100,000 copies/mL 67 (24.9%) 122 (21.9%)
Low self-reported adherenceb (n, %) 113 (42.0%) 252 (45.2%) 0.38
Pill count adherence (n, %)c 0.45
<90% 12 (4.5%) 33 (6.3%)
90−95% 23 (8.6%) 58 (10.5%)
95−100% 233 (87.0%) 463 (83.6%)
Presence of any WHO-defined pretreatment drug resistance 20 (7.4%) 92 (16.5%) <0.001
aP values represent statistical tests comparing those included and excluded from the analytic dataset, using chi-squared testing to compare categorical variables and Mann−Whitney nonparametric tests
to compare median age.
bLow adherence defined as self-report of less than perfect adherence in the 4 days prior to any study visits during the observation period.
cPill count was calculated at each visit by study pharmacists, capped at 100%, then averaged across the 96-week observation period.
0.20
Any WHO NRTI* or
NNRTI* mutation
Any major NRTI mutation
K103N
































Fig. 2 Distribution of WHO-defined pretreatment drug resistance in the
ADVANCE trial, using the WHO Surveillance Drug Mutations list for
mutations detected at >20% of the viral quasispecies. Error bars indicate
95% confidence intervals around the proportion estimates.
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consistent with preliminary data suggesting higher replication of
NNRTI mutant viruses in the context of drug pressure from
integrase inhibitors23, although additional studies would be nee-
ded to corroborate this hypothesis. Whereas we found relatively
little minority resistance and no effect of minority resistance on
outcomes, existence of NNRTI resistance could be a surrogate
marker of archived NRTI resistance24. Integrase resistance
mutations were not assessed in this study, but are generally
believed to be rare (<1%) in this region25,26. Importantly, PDR
did not hamper time to initial virologic suppression or change in
viral load from enrollment to week 12 among people on DTG-
based ART. A similar phenomenon of early maintenance of
suppression followed by longer-term treatment failure was also
seen with DTG monotherapy studies27,28.
Alternatively, the lack of long-term suppression we identified
in the DTG-based ART arms may be due to a behavioral com-
ponent—pre-existing EFV mutations may be a surrogate of prior
default among participants not disclosing previous ART expo-
sure. Our multivariable logistic regression models included a
measure of self-reported adherence and pill count-based adher-
ence, both of which were highly predictive of virologic outcomes.
Addition of these measures to our model did not meaningfully
alter the effect size of PDR on virologic success. However, both
self-reported and pill count-based adherence are imperfect mea-
sures, and can have a relatively low sensitivity to detect poor
adherence, so residual confounding might be present29–31.
Moreover, previous studies have demonstrated that prior ART
exposure is associated with treatment failure and predicts vir-
ologic failure, even after controlling for PDR and treatment
adherence, and thus could be a source of residual confounding if
significant numbers of individuals in this study declined to dis-
close prior ART use32,33. Notably, a number of studies have
reported denial of ART use among individuals determined to be
taking therapy based on drug level testing34–36. The South Afri-
can public HIV program has used EFV in first-line therapy since
its inception in 2004 and has over 5 million on treatment. The
number of individuals who have defaulted and are re-initiating
therapy are likely to be significant, and it is impossible to identify
such individuals within clinical trials using existing South African
data systems. Thus, while our effect size for PDR is large, and
adjusted for confounding, the possibility that prior treatment
exposure is a confounder of this effect remains substantial.
Whether the mechanism of effect is due to poor adherence or
virologic mechanisms, our finding that NNRTI resistance, which
is present in 10−20% of individuals initiating DTG in the region
and is associated with a reduction in efficacy of DTG-based ART,
has multiple public health implications. First, ensuring adequate
virologic monitoring occurs with DTG-based regimens will
remain a priority. Second, treatment programs will require
ongoing attention to second- and third-line options, particularly
if DTG failure or intolerance becomes more common than pre-
viously expected, and NNRTI-based regimens become more
commonly used again. Third, integrase resistance testing, which is
rarely done outside of research studies in resource-limited set-
tings should become a consideration for referral laboratories in
countries where DTG becomes the treatment of choice. Fourth,
our data, in combination with the DAWNING study and others,
highlight that the presence of drug resistance mutations might
portend very different outcomes depending on the timing of
when it occurs. In DAWNING, drug resistance mutations
detected at the time of first-line failure were a surrogate measure
of past adherence and predict success to second-line therapy21. By
contrast, in this study the presence of drug resistance mutations
at presentation for first-line treatment (or re-initiation after a
default) appeared to signal the opposite—increased risk of vir-
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fitness deficit. Making this distinction about the clinical impli-
cations of drug resistance for clinical and public health purposes
could be crucial. Fifth, our findings might signal a warning for
national programs in the midst of large-scale switching from
EFV-based to DTG-based ART, and support increased vigilance
for the presence of treatment failure at the time of switch. Finally,
these results signal the importance of future work to determine
optimal treatment recommendations for individuals failing DTG-
based ART, for which minimal data are currently available.
Without such data, treatment programs should be advised to
maintain virologic monitoring programs, adherence monitoring
and support programs for those with failure, and regimen change
guidance for individuals with intolerance or persistent virologic
failure, even when documented drug resistance is absent. More
novel strategies, such as real-time adherence and resistance
monitoring, and long-acting injectable formulations of ART for
those with adherence challenges should also be explored as these
options become more widely available37–39.
NAMSAL is the only other randomized controlled trial that has
compared DTG vs EFV-based first-line ART in sub-Saharan
Africa. That study, conducted in Cameroon, compared low-dose
400 mg EFV to DTG as third agent at 48 weeks6. DTG was non-
inferior to EFV in that study, but baseline VL > 100,00 copies/mL
predicted failure in both arms. NAMSAL reported a much lower
prevalence of NNRTI resistance (6%) than we did (14%), which is
consistent with other data in the region40. In NAMSAL, inves-
tigators reported no impact of baseline NNRTI resistance on
outcomes, although 6/16 failures in the EFV arm had pre-existing
NNRTI resistance. In that study, none of the three failures in the
DTG arm at 48 weeks had baseline resistance to NNRTIs, the 6%
of those that did appear to suppress during the study. By contrast,
in our study, isolated K103N in the DTG arm was associated with
lower virologic success in the primary analysis, albeit at 96 weeks.
As in prior studies, we identified a very small number of indivi-
duals with resistance to both the NRTI and NNRTI drug classes,
including K65R, M184V who we believe were unlikely to be
treatment naive and who responded poorly to first-line ART.
While the proportion is low, this finding is concerning from the
point of view of the large-scale EFV to DTG-transition in sub-
Saharan Africa, during which multi-class drug resistance is likely
to be more prevalent32,41–44.
Next-generation sequencing is becoming more widely used in
research studies to measure the prevalence and impact of drug
resistance in LMIC, and has the added advantage of being able to
detect resistant viruses at low frequencies45–47. However, many
studies, and particularly those considering newer ART regimens,
have failed to demonstrate a role for these low-level mutant
viruses in determining clinical outcomes48. We also found no
association between PDR and outcome when considering indi-
viduals with mutations in between 2 and 20% of viral quasis-
pecies, which supports current practice to use major resistance
mutation frequencies for determination of clinically significant
drug resistance.
Our study should be generalized in light of its conduct in South
Africa, and the presence of NNRTI resistance-conferring muta-
tions as the large majority of the PDR detected. As this is the first
study to show an impact of PDR on the efficacy of first-line DTG,
it requires corroboration from future studies of similar cohorts.
The presence of a higher prevalence of PDR in the DTG arm
suggests that there might have been imbalance between groups,
which is most likely due to chance, because the study arm was
determined by computer randomization. Nonetheless, we have
low suspicion for selective dropout in the study because interest
in DTG among patients and within society at the time of
1.00
P = 0.002 P < 0.001 P = 0.001P < 0.001
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Fig. 3 Virologic success in the ADVANCE Trial divided by the presence or absence of WHO-defined pretreatment major drug mutations and by use of
efavirenz- or dolutegravir-based regimen. Results are for virologic success defined by our primary outcome (a), secondary outcome (b), FDA 48-week
Snapshot (c), and FDA 96-week Snapshot (d). Error bars indicate 95% confidence intervals around the proportion estimates. P values represent results of
two-sided two-proportion Z tests.
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randomization was minimal. Our estimates could be susceptible
to unmeasured or residual confounding, particularly due to the
effects of prior ART exposure and/or imperfect adherence not
captured by self-report or pharmacy pill counts. Notably, our
estimates of the effect of PDR on virologic outcomes remained
large and significant after adjustment for confounders, including
adherence, meaning an unmeasured confounder would have to
have a strong association (OR of 2.7 or greater) with both PDR
and virologic success to reduce the effect of pretreatment drug
resistance to null22. Yet, prior studies have shown such an effect
size for prior ART exposure33,49. Notably, known predictors of
treatment success, such as adherence and pretreatment viral load,
each predicted virologic success, which enhances the internal
validity of our estimates. We also were unable to sequence
approximately 15% of the study cohort due to unavailable spe-
cimens or failed sequencing. Despite that, our sample size
remained large enough to detect relatively small changes in out-
comes, and we detected no differences in characteristics between
those who were and were not included in this sub-study, which
reduces the risk of selection bias. Finally, our sequencing did not
include the integrase region of the pol gene. Although resistance
mutations that confer resistance to dolutegravir remain rare in
South Africa, we cannot exclude the possibility of low-level
resistance as a possible contributor to our findings25,26.
In summary, our study suggests that the presence of PDR to
NNRTIs is negatively associated with long-term virologic out-
come of both EFV- and DTG-based first-line ART in South
Africa. In the context of highly prevalent PDR NNRTI resistance,
our findings, if corroborated, have implications for first-line ART
selection and treatment monitoring guidelines in the region.
Future work should validate our findings, assess the contribution
of pretreatment integrase mutations to outcomes, elucidate the
impact of prior exposure to ART on treatment outcomes, and
Table 3 Logistic regression models for 96-week virologic success in the ADVANCE Trial (virologic success in our primary
outcome was defined as achievement of a sustained viral load <1000 copies/mL from 12 weeks, <200 copies/mL from 24 weeks,
and <50 copies/mL from 48 weeks onwards. Individuals who are censored after 48 weeks with virologic suppression are
considered as achieving virologic success).
Covariable Univariable models Baseline viral load-adjusted
multivariable model
Fully adjusted multivariable model
Odds ratio
(95%CI)
P valuea Adjusted odds ratio
(95%CI)
P valuea Adjusted odds ratio
(95%CI)
P valuea
Female Sex 0.90 (0.62, 1.29) 0.59 0.82 (0.54, 1.25) 0.35
Age (each year) 1.05 (1.02, 1.07) <0.001 1.02 (0.99, 1.05) 0.14
Married or partner 1.38 (0.86, 2.23) 0.18 0.95 (0.56, 1.60) 0.84
Tertiary education 0.83 (0.45, 1.54) 0.66 0.81 (0.41, 1.57) 0.53
Employed 2.07 (1.43, 2.98) <0.001 1.77 (1.17, 2.67) 0.01
Pretreatment CD4 count
≤200 cells/μL REF REF
201−350 cells/μL 1.31 (0.83, 2.07) 0.25 1.27 (0.76, 2.13) 0.37
351−500 cells/μL 1.12 (0.67, 1.87) 0.66 0.98 (0.54, 1.77) 0.95
>500 cells/μL 1.13 (0.68, 1.88) 0.63 0.99 (0.54, 1.83) 0.97
Pre-treatment viral load
<10,000 copies/mL REF REF REF
10,000−100,000 copies/mL 0.59 (0.37, 0.92) 0.02 0.56 (0.36, 0.89) 0.01 0.52 (0.31, 0.88) 0.01
>100,000 copies/mL 0.49 (0.29, 0.82) 0.006 0.51 (0.30, 0.85) 0.01 0.39 (0.21, 0.72) 0.003
Low self-reported adherenceb (n, %) 0.36 (0.25, 0.52) <0.001 0.41 (0.27, 0.63) <0.001
Pill count adherence (n, %)c
<90% REF REF
90−95% 2.99 (1.39, 6.43) 0.005 2.71 (1.15, 6.38) 0.02
95−100% 6.16 (3.31, 11.46) <0.001 3.51 (1.70, 7.24) 0.001
Regimen
Efavirenz-based regimen REF REF REF
Dolutegravir-based regimen 0.80 (0.54, 1.18) 0.26 0.90 (0.22, 0.53) 1.02 (0.67, 1.57) 0.92
Presence of WHO-defined
pretreatment drug resistance
0.33 (0.22, 0.52) <0.001 0.34 (0.22, 0.53) <0.001 0.38 (0.23, 0.61) <0.001
aP values represent results of two-sided tests of significance for coefficients in multivariable logistic regression models.
bLow adherence defined as self-report of less than perfect adherence in the 4 days prior to any study visits during the observation period.
























>95% adherence/no major drug mutations
<95% adherence/no major drug mutations
>95% adherence/≥1 drug resistance mutation*




Fig. 4 96-week treatment outcomes among participants in the ADVANCE
Trial divided by treatment arm, presence or absence of WHO-defined
pretreatment drug resistance, and achievement of greater than vs less
than 95% adherence based on pharmacy pill count. Error bars represent
95% confidence intervals of the proportion estimates.
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whether treatment failure observed on DTG-based ART is asso-
ciated with emergence of integrase inhibitor mutations.
Methods
Study design. The ADVANCE trial is an open-label, non-inferiority, phase three
clinical trial comparing three regimens for the initial treatment of HIV
(NCT03122262). Individuals were recruited from 11 public HIV clinics in
Johannesburg, South Africa. All study visits and data collection procedures were
performed at one of two research clinics in Johannesburg operated by the study
staff. Consenting participants were randomized in a 1:1:1 ratio to (i) tenofovir
disoproxil fumarate (TDF), emtricitabine (FTC), EFV; (ii) TDF, FTC, DTG, or (iii)
tenofovir alafenamide (TAF), FTC, and DTG50. The study enrolled non-pregnant
individuals over 12 years old without chronic kidney disease. Individuals were
excluded if they had more than 30 days of prior ART use, any ART use in the past
6 months, were pregnant, or were actively undergoing therapy for tuberculosis.
Study visits and measures. Study participants were seen for screening and ran-
domization visits, which included collection of blood for pretreatment viral load
and CD4 T-cell count measurements. Data on demographics, employment, marital
status, and education attainment were collected. During observation, participants
were scheduled for visits at week 4, 12, then every 12 weeks thereafter. Data for this
analysis are limited to 96 weeks of observation. At each follow-up visit, plasma was
collected for viral load estimation. Participants were asked about self-reported
adherence over the past 4 days prior to each visit. Finally, study pharmacists
recorded dispensed pills and performed a pill count of remaining pills at each
follow-up visit. Pretreatment plasma specimens were shipped to KwaZulu-Natal
Research Innovation and Sequencing Platform (KRISP) for extraction (Chemagic
360; Perkin Elmer, Germany), HIV-1 pol gene amplification (ThermoFisher HIV-1
genotype amplification module; Life Technologies, CA, USA), and next-generation
sequencing (Illumina MiSeq; llumina, CA, USA) as previously described51. We
limited our analyses to sequences with ≥100× depth of coverage and spanning PR
codons 1–99 and RT codons 1–254 (Supplemental Fig. 3).
Statistical analysis. We first described and graphically depicted the analytic
sample to determine which study participants were included and excluded from
this analysis. To assess for selection bias in this sub-analysis, we compared char-
acteristics between individuals who had sequencing results available for this ana-
lysis with those who did not due to lack of available plasma specimens or failed
sequencing. We then summarized clinical and demographic features of the analytic
sample in total, and divided into those initiating EFV and DTG-based regimens.
We then described the frequency and proportion of WHO-assigned PDR muta-
tions overall, by drug class, and by treatment regimen.
Our primary exposure of interest was PDR, which we defined as the presence of
at least one of the WHO list of surveillance drug mutations detected in at least 20%
of the viral population52. Our primary outcome of interest was 96-week virologic
success, which we defined as sustained a viral load <1000 copies/mL from 12 weeks
through 96 weeks, <200 copies/mL from 24 weeks through 96 weeks, and <50
copies/mL from 48 weeks through 96 weeks. Individuals censored with virologic
suppression at 48 weeks or after are considered to have achieved virologic success.
Individuals who did not complete 12 weeks of observation are not included in this
analysis (but are included in the 48- and 96-week Food and Drug Administration
[FDA] Snapshot sensitivity outcomes as failures, as described below). We derived
this definition to reflect treatment response in individuals who attain and maintain
virologic suppression over the course of study observation. We estimated the
proportion of participants who achieved virologic suppression by the presence or
absence of PDR for the total cohort, and by EFV vs DTG treatment regimens.
We fitted logistic regression models with virologic success as the outcome of
interest to estimate the contributions of both PDR and regimen to 96-week virologic
success, with and without a regimen by PDR product interaction term to assess
whether the effect of PDR differed by EFV vs DTG use. We then fitted multivariable
logistic regression models with virologic success as the outcome of interest, including
the following potential confounding variables, which have been shown to determine
virologic success in prior work53,54: sex, age, partnership status (defined as married or
with a primary partner vs not), educational attainment (dichotomized as tertiary
education or less), active employment status, pretreatment CD4 T-cell count
(categorized as ≤200 cells/μL, 201−350 cells/μL, 351−500 cells/μL, and >500 cells/μL),
pretreatment viral load (categorized as <10,000 copies/mL, 10,000−100,000 copies/mL,
>100,000 copies/mL), pill count-based adherence (calculated as the number of pills
taken since the prior visit divided by the expected number of pills taken, capped at
100% at each visit, averaged over the course of the 96-week observation period, and
categorized as 95−100%, 90−95%, and <90% average adherence), and self-reported
adherence (dichotomized as perfect adherence in the past 4 days vs any treatment
interruptions in the past 4 days). We assessed for collinearity in our model by
estimating variation initiation factors for each covariate within our fully adjusted
model (Supplemental Table 7). In a third model intended to focus more directly on the
virologic factors that determine treatment outcome, we restricted the model to
pretreatment viral load, presence or absence of PDR, and study treatment allocation.
In sensitivity analyses, we varied our definition of virologic success. To assess
for the impact of NNRTI PDR on persistent virologic failure, for a secondary
outcome we defined success in individuals without two consecutive visits up to
96 weeks with a viral load >200 copies/mL. In this definition, individuals censored
or changed to a second-line regimen after a single viral load >200 copies/mL are
considered failures, whereas those who discontinue with virologic suppression are
considered as achieving virologic success. This outcome is meant to detect persist
virologic failure by allowing for virologic blips or episodic failure followed by re-
suppression. To assess the contribution of PDR on virologic response to therapy,
we also considered a virologic potency outcome defined by the change in log10 viral
load from enrollment to week 12, and assessed for time to first virologic
suppression using Kaplan−Meier survival methods. In the survival analyses,
individuals were censored at the time of first virologic suppression and considered
failures if that occurred with a detectable viral load. We also conducted analyses
using the FDA-defined 48-week and 96-week Snapshot to define virologic success.
In these analyses, individuals who dropped out prior to the 48- and 96-week
windows are considered as failures, irrespective of the reason. We considered three
stratified analyses in which we (1) restricted the definition of PDR to individuals
with only the K103N mutation, (2) restricted the definition of PDR to individuals
who had WHO-defined PDR mutations at variant frequencies of 2−20%, and (3)
assessed finding stratified by those in the EFV- or DTG-based arms. In a subset of
individuals who had sequencing data available both prior to treatment initiation
and after failure, we compared changes in patterns of NRTI and NNRTI-class
resistance over time. We also conducted restricted analysis to individuals with
sequences with ≥100× depth of coverage. Finally, we estimate an E value to
determine the magnitude of the effect size of an unmeasured confounder who need
to have to reduce the association between PDR and virologic success to null22. Data
analysis was conducted in Stata (Version 15.1, Statacorp, College Station, Texas,
USA), coded by two separate investigators (M.J.S. and B.S.) and compared for
reproducibility. A fully de-identified dataset and code for all analyses are available
upon request to the corresponding author.
Ethical considerations. The study was approved by the institutional review board
at the University of the Witwatersrand. All study participants gave written
informed consent to participate.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Full data are available from Professor Ravi Gupta (rkg20@cam.ac.uk) or Professor
Francois Venter (fventer@ezintsha.org). Sequences generated in this study are available
from SRA: https://www.ncbi.nlm.nih.gov/sra under accession number: PRJNA669549.
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